Nisulid

Nisulid may be available in the countries listed below.

Ingredient matches for Nisulid

Nimesulide

Nimesulide is reported as an ingredient of Nisulid in the following countries:

• Brazil


• Chile


• Switzerland

International Drug Name Search

Sinaprid

Sinaprid may be available in the countries listed below.

Ingredient matches for Sinaprid

Sulpiride

Sulpiride is reported as an ingredient of Sinaprid in the following countries:

• Tunisia

International Drug Name Search

Festal N

Festal N may be available in the countries listed below.

Ingredient matches for Festal N

Pancreatin

Pancreatin is reported as an ingredient of Festal N in the following countries:

• Bulgaria


• Turkey

International Drug Name Search

Lanobax

Lanobax may be available in the countries listed below.

Ingredient matches for Lanobax

Lansoprazole

Lansoprazole is reported as an ingredient of Lanobax in the following countries:

• Estonia


• Latvia


• Lithuania

International Drug Name Search

Omepren-20

Omepren-20 may be available in the countries listed below.

Ingredient matches for Omepren-20

Omeprazole

Omeprazole is reported as an ingredient of Omepren-20 in the following countries:

• Sri Lanka

International Drug Name Search

Mesporin

Mesporin may be available in the countries listed below.

Ingredient matches for Mesporin

Ceftriaxone

Ceftriaxone disodium salt (a derivative of Ceftriaxone) is reported as an ingredient of Mesporin in the following countries:

• Costa Rica


• El Salvador


• Estonia


• Guatemala


• Honduras


• Hong Kong


• Latvia


• Lithuania


• Malaysia


• Nicaragua


• Panama


• Trinidad & Tobago

International Drug Name Search

Nitroglycerin

In some countries, this medicine may only be approved for veterinary use.

In the US, Nitroglycerin (nitroglycerin systemic) is a member of the following drug classes: antianginal agents, vasodilators and is used to treat Angina, Angina Pectoris Prophylaxis, Heart Attack, Heart Failure, High Blood Pressure and Raynaud's Syndrome.

US matches:

• Nitroglycerin


• Nitroglycerin Controlled-Release Capsules


• Nitroglycerin Ointment


• Nitroglycerin Patch


• Nitroglycerin Spray


• Nitroglycerin Tablets


• Nitroglycerin oral/sublingual


• Nitroglycerin topical


• Nitroglycerin transdermal


• Nitroglycerin Intravenous


• Nitroglycerin Oral, Sublingual


• Nitroglycerin Dextrose


• Nitroglycerin Lingual Spray


• Nitroglycerin Slocaps


• Nitroglycerin Sublingual Tablet


• Nitroglycerin Tablet


• Nitroglycerin in Dextrose

Scheme

USAN

ATC (Anatomical Therapeutic Chemical Classification)

C01DA02,C05AE01

CAS registry number (Chemical Abstracts Service)

0000055-63-0

Chemical Formula

C3-H5-N3-O9

Molecular Weight

227

Therapeutic Categories

Vasodilator

Muscle relaxant

Chemical Name

1,2,3-Propanetriol, trinitrate

Foreign Names

• Glyceroli trinitratis (Latin)
• Glyceroltrinitrat (German)
• Trinitrine (French)

Generic Names

• Nitroglycerin (OS: USAN, JAN)
• Trinitrine (OS: DCF)
• DR 66 (IS)
• Nitroglycerol (IS)
• Nitromed (IS)
• Glyceroli trinitratis solutio (PH: Ph. Eur. 6)
• Glyceryl Trinitrate Solution (PH: Ph. Eur. 6, BP 2010)
• Glyceryl Trinitrate, Concentrated Solution (PH: BP 2002)
• Nitroglicerina (PH: F.U. XII)
• Nitroglycerin, Diluted (PH: USP 32)

Brand Names

• Adesitrin
  Pfizer, Italy



• Angicard
  Drug International, Bangladesh



• Anginine
  Sigma, Australia



• Angiolingual
  Royal Pharma, Chile



• Angised
  GlaxoSmithKline, United Arab Emirates; GlaxoSmithKline, Bosnia & Herzegowina; GlaxoSmithKline, Bangladesh; GlaxoSmithKline, Bahrain; GlaxoSmithKline, Cyprus; GlaxoSmithKline, Hong Kong; GlaxoSmithKline, Israel; GlaxoSmithKline, India; GlaxoSmithKline, Iran; GlaxoSmithKline, Jordan; GlaxoSmithKline, Kuwait; GlaxoSmithKline, Lebanon; GlaxoSmithKline, Oman; GlaxoSmithKline, Qatar; GlaxoSmithKline, Singapore; GlaxoSmithKline, Slovenia; GlaxoSmithKline, Syria; GlaxoSmithKline, Yemen; GlaxoSmithKline, South Africa



• Angispan
  USV, India



• Anril
  Square, Bangladesh



• Cafinitrina (Nitroglycerin and Caffeine)
  Almirall, Spain



• Corangin Nitrospray
  Mibe, Germany



• Cordipatch
  UCB, France



• Cordiplast
  Schwarz, Spain



• Coro-Nitro
  Ayrton Saunders, United Kingdom



• Dauxona
  Northia, Argentina



• Deponit NT
  Adeka, Turkey



• Deponit
  Altana, Belgium; Delphi, Netherlands; Dr. Fisher, Netherlands; EU-Pharma, Netherlands; Eurim, Austria; Euro, Netherlands; Medcor, Netherlands; Nycomed, Netherlands; Schwarz, Austria; Schwarz, China; Schwarz, Germany; Schwarz, Hong Kong; Schwarz, Israel; Schwarz, Italy; Schwarz, Sri Lanka; Schwarz, Lithuania; Schwarz, Luxembourg; Schwarz, Malaysia; Schwarz, Peru; Schwarz, Philippines; Schwarz, Singapore; Schwarz, United States; UCB, Finland; UCB Pharma, United Kingdom; UCB-Pharma, Switzerland



• Dermatrans
  Bayer, Italy; Recordati, Spain



• Diafusor
  Pierre Fabre, Spain; Pierre Fabre, Tunisia; Pierre Fabre Médicament, France; Schering-Plough, Belgium; Schering-Plough, Luxembourg



• Discotrine
  3M, Iceland; Meda, Denmark; Meda, France



• Domitral
  Domesco, Vietnam



• Dydrene
  Towa Yakuhin, Japan



• Enetege
  Fada, Argentina



• Epinitril
  Bouchara, France; Delta, Portugal; Rottapharm, Spain; Rottapharm, Greece; Rottapharm, Italy



• Gallolingual
  Pohl-Boskamp, Germany



• Gen-Nitro
  Genpharm, Canada



• Glyceryl Trinitrate DBL
  Orna, Turkey



• Glyceryl Trinitrate
  DBL/Faulding, Bangladesh; Health Support Ltd, New Zealand; Hospira, Australia; Hospira, Indonesia; Hospira, New Zealand; Hospira, Taiwan; Tempo Scan Pacific, Indonesia



• Glycerylnitrat SAD
  Amgros, Denmark



• Glycerylnitrat
  Nycomed, Norway



• Glytrin Spray
  AFT, New Zealand; Sanofi-Aventis, Ireland



• Glytrin
  Meda, Denmark; Meda, Sweden; Pharmasol, Singapore; Sanofi-Aventis, United Kingdom; Square, Bangladesh



• Keritrina
  Keryos, Italy



• Limitral
  Domesco, Vietnam



• Loion
  Pharmapol, Germany



• Lycinate
  Fawns & McAllan, Australia; Healthcare Logistics, New Zealand



• Meditrans
  Kyowa Hakko Kirin, Japan; Sekisui Medical, Japan



• Millis
  Nippon Kayaku, Japan



• Millisrol
  Khandelwal, India; Nippon Kayaku, Japan; Nippon Kayaku, Taiwan



• Millistape
  Nippon Kayaku, Japan



• Minitran
  Douglas, New Zealand; Graceway, United States; Graceway Pharmaceuticals, Canada; Meda, Belgium; Meda, Switzerland; Meda, United Kingdom; Meda, Italy; Meda, Luxembourg; Meda, Netherlands; Meda, Sweden; Meda Pharma Sau, Spain



• Minitrans
  3M, Argentina; 3M, Finland; 3M, Malta; 3M, Philippines; 3M, United States; Graceway Pharmaceuticals, Canada; iNova Pharmaceuticals, Australia; Meda, Germany; Meda, Malta



• Minitro
  Kyorin Rimedio, Japan



• Myocor
  Toa Eiyo, Japan



• Myonit
  Troikaa, India



• Myovin
  Cadila, India



• Natispray
  Procter & Gamble, Luxembourg; Procter & Gamble, Tunisia; Teofarma, France; Teofarma, Italy



• Nidocard Retard
  Drug International, Bangladesh



• Niglinar
  ALM, Peru; Rivero, Argentina



• Nirmin
  Zorka, Serbia



• Nitracor
  Pliva, Poland



• Nitradisc
  Continental, Luxembourg; Pfizer, Argentina; Pfizer, Brazil; Pfizer, Spain; Pfizer, Portugal



• Nitraket
  3M, Italy; Meda, Italy



• Nitrangin Isis
  Actavis, Germany



• Nitrangin Pumpspray
  Actavis, Germany



• Nitrek
  Bertek, United States



• Nit-Ret Slovakofarma
  Slovakofarma, Czech Republic; Zentiva, Slovakia



• Nitriderm TTS
  Novartis, France



• Nitrin SR
  Healthcare, Bangladesh



• Nitro Carino
  Carinopharm, Germany



• Nitro Dur
  Eureco, Netherlands; Schering-Plough, Spain; Schering-Plough, Hungary; Schering-Plough, Netherlands; Schering-Plough, Portugal



• Nitro Mack Retard
  Mack, United Arab Emirates; Mack, Bahrain; Mack, Cyprus; Mack, Egypt; Mack, Jordan; Mack, Kuwait; Mack, Lebanon; Mack, Oman; Mack, Qatar; Mack, Saudi Arabia



• Nitro Mack
  Mack, Luxembourg



• Nitro Pohl
  Pohl, Czech Republic; Pohl, Hungary; Pohl, Lithuania; Pohl, Latvia; Pohl, Netherlands; Sanova, Austria



• Nitro
  Orion, Finland; Orion, Georgia; Orion, Latvia; Orion, Russian Federation



• Nitro-Bid
  Fougera, United States



• Nitrocap
  Orion, Bangladesh



• Nitrocard
  Aristopharma, Bangladesh; Chema, Poland; Zuoz, Venezuela



• Nitrocine
  Briz, Latvia; Pharos, Indonesia; Schwarz, Estonia; Schwarz, Hong Kong; Schwarz, Israel; Schwarz, Sri Lanka; Schwarz, Lithuania; Schwarz, Latvia; Schwarz, Malaysia; Schwarz, Singapore; Schwarz, Thailand; UCB, Indonesia; UCB, Ireland; UCB, South Africa; UCB Pharma, United Kingdom



• Nitrocontin
  Modi-Mundipharma, Bangladesh; Modi-Mundipharma, India; Modi-Mundipharma, Sri Lanka



• Nitrocor Retard
  PMP, Vietnam



• Nitrocor
  3M, Chile; Pharmaceutical, Venezuela; Pharmstandart, Russian Federation; Recordati, Italy



• Nitroderm Matrix
  Novartis, Spain



• Nitroderm TTS
  Novartis, Argentina; Novartis, Austria; Novartis, Belgium; Novartis, Brazil; Novartis, Switzerland; Novartis, Chile; Novartis, Germany; Novartis, Spain; Novartis, Ghana; Novartis, Hong Kong; Novartis, Hungary; Novartis, Israel; Novartis, India; Novartis, Italy; Novartis, Japan; Novartis, Kenya; Novartis, Luxembourg; Novartis, Libya; Novartis, Malta; Novartis, Malaysia; Novartis, Nigeria; Novartis, New Zealand; Novartis, Oman; Novartis, Poland; Novartis, Portugal; Novartis, Romania; Novartis, Sudan; Novartis, Slovenia; Novartis, Slovakia; Novartis, Thailand; Novartis, Turkey; Novartis, Taiwan; Novartis, Tanzania; Novartis, Venezuela; Novartis, Zimbabwe



• Nitrodom
  Dominguez, Argentina



• Nitro-Dur
  Essex Chemie, Switzerland; Eureco, Netherlands; Key, United States; Schering, Poland; Schering, United States; Schering-Plough, Argentina; Schering-Plough, Australia; Schering-Plough, Canada; Schering-Plough, United Kingdom; Schering-Plough, Hong Kong; Schering-Plough, Ireland; Schering-Plough, Mexico; Schering-Plough, Netherlands; Schering-Plough, Norway; Schering-Plough, Serbia; Schering-Plough, Slovenia; Sigma Tau, Italy



• Nitrodyl
  Schering-Plough, Greece; Therabel, Luxembourg



• Nitrogard
  Forest, United States



• Nitrogesic
  Troikaa, India



• Nitroglicerin
  Srbolek, Serbia



• Nitroglicerina Bioindustria Lim
  Bioindustria Lim, Italy



• Nitroglicerina L.CH.
  Chile, Chile



• Nitroglicerina PH&T
  PH&T, Italy



• Nitroglicerina Richmond
  Richmond, Argentina



• Nitroglicerina
  Abbott, Peru; Biosano, Chile; Pharmakin, Venezuela; Richmond, Peru; Ryan, Colombia; Sanderson, Chile; Volta, Chile



• Nitroglicerinã
  Zentiva, Romania



• Nitroglicerol
  Bosnalijek, Bosnia & Herzegowina



• Nitroglycerin Bioren
  Sintetica-Bioren, Switzerland



• Nitroglycerin BMM Pharma
  BMM Pharma, Sweden



• Nitroglycerin Dak
  Nycomed, Denmark



• Nitroglycerin in 5% Dextrose Injection
  Abbott, United States; Baxter, Canada; Baxter, United States; Braun, United States



• Nitroglycerin Injection
  Abbott, United States; American Regent, United States



• Nitroglycerin Nycomed
  Nycomed, Estonia; Nycomed, Lithuania



• Nitroglycerin Recip
  Recip, Sweden



• Nitroglycerin Slocaps
  Eon, United States



• Nitroglycerin Slovakofarma
  Slovakofarma, Czech Republic; Zentiva, Slovakia



• Nitroglycerin Streuli
  Streuli Pharma, Switzerland



• Nitroglycerin Transdermal System
  Hercon, United States; Mylan, United States



• Nitroglycerin
  Actavis, Norway; Baxter, United States; Ethex, United States; Fougera, United States; Genom, Georgia; Hercon, United States; Hospira, United States; Kremers-Urban, United States; Luitpold, United States; Mylan, United States; SoloPak, United States; United Research, United States



• Nitroglycerine Amps
  Taro, Israel



• Nitroglycerine
  Bipharma, Netherlands; Nippon Kayaku, Japan; Sandoz, Netherlands



• Nitroglycerinum
  Lek, Lithuania; Lek, Poland



• Nitroject
  Sun, Russian Federation



• Nitrokaf Retard
  Kimia Farma, Indonesia



• Nitrol
  Paladin, Canada



• Nitrolingual
  Codali, Luxembourg; Douglas, New Zealand; Farma-Tek, Turkey; First Horizon, United States; Lavipharm, Greece; Lubapharm, Switzerland; Medis, Bosnia & Herzegowina; Medis, Slovenia; Medis Adria, Croatia (Hrvatska); Megapharm, Israel; Merck, Ireland; Merck Serono, United Kingdom; Merck Serono, South Africa; Pharmapol, Germany; Pohl, Denmark; Pohl, Hungary; Pohl, Lithuania; Pohl, Malta; Pohl, Netherlands; Pohl, Serbia; Pohl, Sweden; Pohl, Singapore; Pohl Boskamp, Norway; Pohl-Boskamp, Germany; Pohl-Boskamp, Oman; Sanofi-Aventis, Australia; Sanofi-Aventis, Canada; Sanova, Austria; Shionogi, United States; Tramedico, Belgium; Tramedico, Luxembourg; Weal-Chance, Taiwan



• Nitro-Mack
  Galenica, Greece; Mack, Ethiopia



• Nitromex
  Actavis, Denmark; Actavis, Finland; Actavis, Norway; Actavis, Sweden; Alpharma, Iceland



• Nitromin
  Servier, Ireland; Teva Pharmaceuticals, United Kingdom



• Nitromint
  Egis, Bangladesh; Egis, Czech Republic; Egis, Egypt; Egis, Georgia; Egis, Hungary; Egis, Lithuania; Egis, Latvia; Egis, Poland; Egis, Romania; Egis, Russian Federation; Egis, Slovakia; Egis, Syria; Egis, Thailand; Egis, Vietnam; Egis, Yemen; Rhône-Poulenc, Portugal



• NitroMist
  NovaDel Pharma, United States



• Nitronal
  Douglas, New Zealand; Farma-Tek, Turkey; Medinam, Bangladesh; Medis, Slovenia; Megapharm, Israel; Merck Serono, United Kingdom; Pharmapol, Germany; Pohl, France; Pohl-Boskamp, Oman



• Nitronal-A
  Lubapharm, Switzerland



• Nitronalspray
  Pohl, France



• Nitrong
  Krka, Georgia; Krka, Lithuania; Krka, Latvia; Lavipharm, Greece



• Nitropack
  Farmindustria, Peru



• Nitropen
  Nippon Kayaku, Japan; Pharmanova, Serbia



• Nitroplast
  Lacer, Spain



• Nitroquick
  Ethex, United States



• Nitroretard Faran
  Faran Laboratories, Greece



• Nitrospray-ICN
  Pharmstandart, Russian Federation



• Nitrostad Retard
  Stada, Vietnam



• Nitrostat
  Pfizer, Canada; Pfizer, Philippines; Pfizer, Taiwan; Pfizer, United States



• Nitrosylon
  Abbott, Italy; Lavipharm, Greece



• Nitro-Time
  Time-Cap, United States



• Nitrovas SR
  Popular, Bangladesh



• Nitroven
  Pohl Boskamp, Norway



• Nyrocin
  Vee Excel, Myanmar



• Nysconitrine
  Therabel, Luxembourg



• Pancoran
  Novartis, Greece



• Pentaerythritol compositum (Nitroglycerin and Pentaerithrityl Tetranitrate)
  Galena, Poland



• Percutol
  Pliva Pharma, United Kingdom



• Percutol (veterinary use)
  Pliva Animalhealth, United Kingdom



• Perganit
  AstraZeneca AB-S, Italy



• Perlinganit Roztok
  Schwarz, Czech Republic



• Perlinganit
  Adeka, Turkey; Schwarz, Austria; Schwarz, Germany; Schwarz, Finland; Schwarz, Luxembourg; Schwarz, Philippines; Schwarz, Poland; Schwarz, Russian Federation; UCB-Pharma, Switzerland



• Plastranit
  Jaba, Portugal



• Rectogesic
  APS, Germany; Care Pharmaceuticals, Australia; Care Pharmaceuticals, Singapore; Clonmel, Ireland; Farmasel, Turkey; Ferring, Poland; Medius, Switzerland; ProStrakan, Denmark; ProStrakan, France; ProStrakan, United Kingdom; ProStrakan, Hungary; ProStrakan, Norway; ProStrakan, Sweden; Prostrakan Farmaceutica, Spain



• Rho-Nitro
  sanofi-aventis, Canada



• Solinitrina
  Almirall, Spain



• Supranitrin
  Gap, Greece



• Suscard Buccal
  Pharmax, United Arab Emirates; Pharmax, Bahrain; Pharmax, Cyprus; Pharmax, Ireland; Pharmax, Jordan; Pharmax, Kuwait; Pharmax, Qatar; Pharmax, Yemen



• Suscard
  BMM Pharma, Sweden; Forest, United Kingdom



• Sustac
  Forest, United Kingdom; Krka, Georgia; Krka, Hungary; Krka, Lithuania; Krka, Latvia; Pharmax, United Arab Emirates; Pharmax, Bahrain; Pharmax, Cyprus; Pharmax, Ireland; Pharmax, Jordan; Pharmax, Kuwait; Pharmax, Oman; Pharmax, Qatar; Pharmax, Yemen



• Sustonit
  Polfa Warshavskiy, Russian Federation; Polfa Warszawa, Poland



• Topi-Nitro
  Schering-Plough, Luxembourg



• Top-Nitro
  Schering-Plough, Italy



• Transderm-Nitro
  Novartis, United Arab Emirates; Novartis, Bahrain; Novartis, Canada; Novartis, Egypt; Novartis, Iraq; Novartis, Iran; Novartis, Jordan; Novartis, Kuwait; Novartis, Lebanon; Novartis, Philippines; Novartis, Qatar; Novartis, Saudi Arabia; Novartis, Syria; Novartis, Yemen



• Transiderm Nitro
  Novartis, Australia; Novartis, Finland; Novartis, United Kingdom; Novartis, Ireland; Novartis, Netherlands



• Transiderm-Nitro
  Novartis, Norway; Novartis, Sweden



• Tridil
  Cristália, Brazil



• Trimonit
  Sanofi-Aventis, Poland



• Trinipatch
  Fournier, Belgium; Fournier, Luxembourg; Megapharm, Israel; Novartis, Canada; Procter Gamble, Spain; Sanofi-Aventis, France; Sanofi-Synthelabo, Greece



• Triniplas
  Novartis, Italy



• Trinispray
  Sanofi-Aventis S.A., Spain



• Trinitrin Simplex Laleuf
  Sanofi, Switzerland



• Trinitrina
  Acarpia-P, Italy



• Trinitrine Merck
  Mylan, France



• Trinitrine Simple Laleuf
  Biologiques de l'Ile-de-France, Tunisia; Johnson & Johnson, France



• Trinitroglicerina Fabra
  Fabra, Argentina



• Trinitron
  Quesada, Argentina



• Trinitrosan
  Merck, Germany; Merck, Croatia (Hrvatska); Merck KGaA, Romania



• Trintek
  Goldshield, United Kingdom



• Trocer
  Incepta, Bangladesh



• Vasolator
  Sanwa Kagaku, Japan



• Venitrin
  3M Santé-F, Italy



• Vernies
  Parke Davis, Spain



• Will long
  Will, Luxembourg



• Willlong
  Will, Belgium

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Neurium

Neurium may be available in the countries listed below.

Ingredient matches for Neurium

Lamotrigine

Lamotrigine is reported as an ingredient of Neurium in the following countries:

• Brazil

Thioctic Acid

Thioctic Acid is reported as an ingredient of Neurium in the following countries:

• Germany

Thioctic Acid ethylenediamine (a derivative of Thioctic Acid) is reported as an ingredient of Neurium in the following countries:

• Germany

International Drug Name Search

Flomoxef Sodium

Flomoxef Sodium may be available in the countries listed below.

Ingredient matches for Flomoxef Sodium

Flomoxef

Flomoxef Sodium (JAN) is also known as Flomoxef (Rec.INN)

International Drug Name Search

Glossary

JAN	Japanese Accepted Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Adermicina

Adermicina may be available in the countries listed below.

Ingredient matches for Adermicina

Retinol

Retinol is reported as an ingredient of Adermicina in the following countries:

• Argentina

International Drug Name Search

Celaskon

Celaskon may be available in the countries listed below.

Ingredient matches for Celaskon

Ascorbic Acid

Ascorbic Acid is reported as an ingredient of Celaskon in the following countries:

• Czech Republic


• Slovakia

International Drug Name Search

Quilonorm

Quilonorm may be available in the countries listed below.

Ingredient matches for Quilonorm

Lithium

Lithium acetate (a derivative of Lithium) is reported as an ingredient of Quilonorm in the following countries:

• Switzerland

International Drug Name Search

Sefeena

Sefeena may be available in the countries listed below.

Ingredient matches for Sefeena

Cefixime

Cefixime is reported as an ingredient of Sefeena in the following countries:

• Japan

International Drug Name Search

Ambroxol Sandoz Conseil

Ambroxol Sandoz Conseil may be available in the countries listed below.

Ingredient matches for Ambroxol Sandoz Conseil

Ambroxol

Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Ambroxol Sandoz Conseil in the following countries:

• France

International Drug Name Search

Dendracin Lotion

Pronunciation: METH-il sa-LIS-i-late/BEN-zoe-kane/MEN-thol
Generic Name: Methyl Salicylate/Benzocaine/Menthol
Brand Name: Dendracin

Dendracin Lotion is used for:

Temporary relief of minor aches and pains caused by arthritis, simple backache, and strains. It may also be used for other conditions as determined by your doctor.

Dendracin Lotion is a topical analgesic. It works by temporarily relieving minor pain.

Do NOT use Dendracin Lotion if:

• you are allergic to any ingredient in Dendracin Lotion, including oil of wintergreen, or to aspirin or other salicylates

Contact your doctor or health care provider right away if any of these apply to you.

Before using Dendracin Lotion:

Some medical conditions may interact with Dendracin Lotion. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have had an allergic reaction to sulfonamides (eg, sulfamethoxazole), para-aminobenzoic acid (PABA), or other topical anesthetics


• if you have a wound at the affected area or your skin is blistered, broken, or damaged in any way

Some MEDICINES MAY INTERACT with Dendracin Lotion. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Anticoagulants (eg, warfarin) because the risk of their side effects may be increased by Dendracin Lotion

Ask your health care provider if Dendracin Lotion may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Dendracin Lotion:

Use Dendracin Lotion as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Shake well before each use.


• Gently rub a thin layer of medicine over the painful or sore area. Check with your doctor or the package label if you have questions about how to apply Dendracin Lotion.


• Wash your hands immediately after using Dendracin Lotion unless your hands are a part of the treated area.


• You may wash the treated area once the medicine has been absorbed into the skin.


• Do not apply Dendracin Lotion to wounds or damaged skin.


• Do not use Dendracin Lotion right after you shower or take a bath.


• Do not bandage, wrap, or cover the affected area until after the medicine has been absorbed and you have washed the area. Do not bandage tightly.


• Do not use Dendracin Lotion more often than 4 times per day.


• If you miss a dose of Dendracin Lotion, use it as soon as you remember. Continue to use it as directed by your doctor or on the package label.

Ask your health care provider any questions you may have about how to use Dendracin Lotion.

Important safety information:

• Dendracin Lotion is for external use only. Do not get it in your eyes, ears, lips, mouth, or genital area. If you get it in any of these areas, rinse right away with cool water.


• Do not use a heating pad after you apply Dendracin Lotion.


• Do not use more than the recommended dose or more often than directed without checking with your doctor.


• Do not use Dendracin Lotion with other topical pain products.


• Do not use Dendracin Lotion over large areas of the body without checking with your doctor.


• Do not allow Dendracin Lotion to come into contact with clothing or any surface other than skin.


• If your symptoms do not get better within 7 days, if they get worse, or if they clear up and then return, check with your doctor.


• Dendracin Lotion may cause harm if it is swallowed. If you may have taken it by mouth, contact your poison control center or emergency room right away.


• Do not use Dendracin Lotion in CHILDREN younger than 12 years old without first checking with the child's doctor; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dendracin Lotion while you are pregnant. It is not known if Dendracin Lotion is found in breast milk after topical use. If you are or will be breast-feeding while you use Dendracin Lotion, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Dendracin Lotion:

All medicines may cause side effects, but many people have no, or minor, side effects. No COMMON side effects have been reported with Dendracin Lotion. Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); signs of infection (eg, oozing, swollen, or blistered skin); skin redness or irritation.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Dendracin side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Dendracin Lotion:

Store Dendracin Lotion below 90 degrees F (32 degrees C). Store away from heat and light. Do not store in the bathroom. Keep Dendracin Lotion out of the reach of children and away from pets.

General information:

• If you have any questions about Dendracin Lotion, please talk with your doctor, pharmacist, or other health care provider.


• Dendracin Lotion is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dendracin Lotion. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Dendracin resources

• Dendracin Side Effects (in more detail)
• Dendracin Support Group
• 3 Reviews for Dendracin - Add your own review/rating

Compare Dendracin with other medications

• Muscle Pain

Medlenik

Medlenik may be available in the countries listed below.

Ingredient matches for Medlenik

Manganese Chloride

Manganese Chloride is reported as an ingredient of Medlenik in the following countries:

• Japan

Zinc Sulfate

Zinc Sulfate is reported as an ingredient of Medlenik in the following countries:

• Japan

International Drug Name Search

Doc Finasteride

Doc Finasteride may be available in the countries listed below.

Ingredient matches for Doc Finasteride

Finasteride

Finasteride is reported as an ingredient of Doc Finasteride in the following countries:

• Belgium


• Luxembourg

International Drug Name Search

Debecylina

Debecylina may be available in the countries listed below.

Ingredient matches for Debecylina

Benzylpenicillin

Benzylpenicillin benzathine (a derivative of Benzylpenicillin) is reported as an ingredient of Debecylina in the following countries:

• Poland

International Drug Name Search

Nocytocine

Nocytocine may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Nocytocine

Oxytocin

Oxytocin is reported as an ingredient of Nocytocine in the following countries:

• France

International Drug Name Search

Gambaran

Gambaran may be available in the countries listed below.

Ingredient matches for Gambaran

Nabumetone

Nabumetone is reported as an ingredient of Gambaran in the following countries:

• Belgium


• Luxembourg

International Drug Name Search

Brimonidine Tartrate

Class: alpha-Adrenergic Agonists
ATC Class: S01EA05
VA Class: OP109
Chemical Name: [S-(R*,R*,)]-2,3-Dihydroxybutanedioate-5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine
Molecular Formula: C₁₁H₁₀BrN₅•C₄H₆O₆
CAS Number: 79570-19-7
Brands: Alphagan P

Introduction

Relatively selective α₂-adrenergic agonist.^{1 3 11 19}

Uses for Brimonidine Tartrate

Ocular Hypertension and Glaucoma

Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.^{1 3 13 19}

Brimonidine Tartrate Dosage and Administration

General

• 
  

  IOP should be determined after about 4 weeks of therapy with the drug; thereafter, IOP should be determined as necessary.¹⁷

  
  

Administration

Topical Administration

Apply topically to the affected eye(s).^{1 19}

If more than one topical ophthalmic drug is used, administer the drugs at least 5 minutes apart.^{1 11 19}

Dosage

Pediatric Patients

Ocular Hypertension and Glaucoma

Ophthalmic

The manufacturer makes no specific dosage recommendations for children ≥2 years of age.¹⁷

Adults

Ocular Hypertension and Glaucoma

Ophthalmic

One drop in the affected eye(s) 3 times daily, approximately 8 hours apart.^{1 11 19}

Cautions for Brimonidine Tartrate

Contraindications

• 
  

  Concomitant use with an MAO inhibitor.^{1 19}

  
  


• 
  

  Known hypersensitivity to brimonidine or any ingredient in the formulation.^{1 19}

  
  

Warnings/Precautions

Sensitivity Reactions

Hypersensitivity Reactions

Ocular hypersensitivity reactions (e.g., allergic conjunctivitis, conjunctival hyperemia, ocular pruritus) reported.¹ If sensitivity reaction occurs, discontinue brimonidine.¹⁷

Possible partial cross-sensitivity between brimonidine and apraclonidine;¹⁸ use with caution in patients with a history of hypersensitivity to apraclonidine.¹⁷

General Precautions

Systemic Effects

Minimal effects on blood pressure in clinical studies; use with caution in patients with severe cardiovascular conditions, depression, orthostatic hypotension, cerebral or coronary insufficiency, Raynaud’s phenomenon, or thromboangiitis obliterans.^{1 19}

IOP Monitoring

IOP-lowering effect of 0.2% brimonidine tartrate ophthalmic solution may diminish over time; routinely monitor IOP.¹⁹

Specific Populations

Pregnancy

Category B.^{1 19}

Lactation

Distributed into milk in rats;^{1 17} discontinue nursing or the drug.^{1 19}

Pediatric Use

Potentially serious adverse CNS effects, including apnea^{8 19} and lethargy reported in infants;^{8 19} not recommended for children < 2 years of age.^{1 6 19}

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.^{1 19}

Common Adverse Effects

With brimonidine tartrate 0.15% ophthalmic solution in adults, allergic conjunctivitis,¹ conjunctival hyperemia,¹ ocular pruritus,¹ burning sensation,¹ conjunctival folliculosis,¹ hypertension,¹ xerostomia,¹ and visual disturbances.¹

With brimonidine tartrate 0.2% ophthalmic solution in adults, oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, ocular pruritus.¹⁹

Age- and weight-related somnolence and decreased mental alertness reported in children 2–7 years of age with glaucoma receiving brimonidine tartrate 0.2% ophthalmic solution.^{1 6 19}

Interactions for Brimonidine Tartrate

No formal drug interaction studies have been performed.^{1 19}

Specific Drugs

Drug	Interaction	Comment
β-Adrenergic blocking agents (topical or systemic)	Additive IOP-lowering and cardiovascular effects3 4 11	Use with caution1 19
Cardiac glycosides	Additive cardiovascular effects11	Use with caution1 19
CNS depressants (e.g., alcohol, barbiturates, general anesthetics, opiates, sedatives)	Additive CNS depressant effects1 19
Hypotensive agents	Additive IOP-lowering and cardiovascular effects3 4 11	Use with caution1 19
MAO inhibitors		Concomitant use contraindicated1 19
Antidepressants, tricyclics (TCAs)	TCAs that affect the metabolism and uptake of circulating amines may interfere with IOP-lowering effect of brimonidine1 19	Use with caution1 19

Brimonidine Tartrate Pharmacokinetics

Absorption

Bioavailability

Peak plasma concentrations occurred within 0.5–4 hours after ocular administration of brimonidine tartrate 0.1 or 0.2% ophthalmic solution.^{1 19}

Onset

Peak ocular hypotensive effects occur 2–3 hours following topical administration of brimonidine.^{1 3 19}

Distribution

Extent

Distributed into milk in animals; not known whether the drug distributes into milk in humans.^{1 19}

Elimination

Metabolism

Extensively metabolized in the liver.^{1 19}

Elimination Route

Brimonidine and its metabolites are excreted principally in urine.^{1 19}

Half-life

2–3 hours.^{1 19}

Stability

Storage

Ophthalmic

Solution

15–25°C.^{1 19}

ActionsActions

• 
  

  Reduces IOP by decreasing aqueous humor production and increasing uveoscleral outflow.^{1 3 4 11 19}

  
  

• 
  

  Selectivity for α₂- versus α₁-adrenergic receptors at least 10 or 28 times greater than that of clonidine or apraclonidine, respectively;^{3 9 11} may result in reduction in adverse pulmonary and cardiovascular effects.^{1 11}

  
  

Advice to Patients

• 
  

  Importance of advising patients that brimonidine tartrate may cause fatigue and/or drowsiness and to exercise caution when engaged in hazardous activities requiring mental alertness.^{1 19}

  
  

• 
  

  Importance of informing patients to administer other ophthalmic drugs at least 5 minutes apart.^{1 19}

  
  


• 
  

  Importance of delaying insertion of soft contact lenses for at least 15 minutes after 0.2% brimonidine tartrate instillation, since benzalkonium chloride preservative in the solution may be absorbed by soft lenses.¹⁹

  
  

• 
  

  Importance of learning and adhering to proper administration techniques to avoid contamination of the solution container.¹⁷

  
  

• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.^{1 19}

  
  

• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.^{1 19}

  
  


• 
  

  Importance of informing patients of other important precautionary information. (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Brimonidine Tartrate

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Ophthalmic	Solution	0.15%	Alphagan P	Allergan
		0.2%*	Brimonidine Tartrate Ophthalmic Solution (with benzalkonium chloride)	Bausch & Lomb

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Alphagan P 0.1% Solution (ALLERGAN): 15/$228.8 or 45/$613.55

Alphagan P 0.1% Solution (ALLERGAN): 10/$149.75 or 30/$422.21

Alphagan P 0.15% Solution (ALLERGAN): 10/$156 or 30/$436.8

Alphagan P 0.15% Solution (ALLERGAN): 15/$228.79 or 45/$650.98

Alphagan P 0.15% Solution (ALLERGAN): 5/$89.31 or 15/$242.22

Brimonidine Tartrate 0.15% Solution (FALCON PHARMACEUTICALS): 10/$115.99 or 30/$329.97

Brimonidine Tartrate 0.15% Solution (FALCON PHARMACEUTICALS): 15/$159.99 or 45/$465.97

Brimonidine Tartrate 0.15% Solution (FALCON PHARMACEUTICALS): 5/$65.99 or 15/$165.97

Brimonidine Tartrate 0.2% Solution (BAUSCH &amp; LOMB): 15/$51.96 or 45/$139.46

Brimonidine Tartrate 0.2% Solution (FALCON PHARMACEUTICALS): 10/$51.99 or 30/$145.97

Brimonidine Tartrate 0.2% Solution (FALCON PHARMACEUTICALS): 5/$31.99 or 15/$89.97

Combigan 0.2-0.5% Solution (ALLERGAN): 5/$87.36 or 15/$245.43

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions July 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

1. Allergan, Inc. Alphagan P (brimonidine tartrate ophthalmic solution) prescribing information. Irvine, CA; 2001 Dec.

2. Allergan, Inc. Alphagan (brimonidine tartrate ophthalmic solution) prescribing information. Irvine, CA; 2001 Dec.

3. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an α₂-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000; 1:815-34. [PubMed 11249518]

4. Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol. 2001; 119:492-5. [IDIS 462462] [PubMed 11296014]

5. Schuman JS, Horwitz B, Choplin NT et al for the Chronic Brimonidine Study Group. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997; 115:847-52. [IDIS 389914] [PubMed 9230823]

6. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS. 2001; 5:281-4. [PubMed 11641636]

7. Serle JB for the Brimonidine Study Group III. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol. 1996; 41(Suppl 1):S39-47.

8. Carlsen JO, Zabriskie NA, Kwon YH et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol. 1999; 128:255-6. [IDIS 432058] [PubMed 10458196]

9. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996; 41(Suppl 1):S19-26. [PubMed 8970246]

10. Melamed S, David R for the Brimonidine Study Group II. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Clin Ther. 2000; 22:103-11. [IDIS 442936] [PubMed 10688394]

11. Maus TL, Nau C, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 1999; 117:586-91. [IDIS 428176] [PubMed 10326954]

12. Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma. 2000; 9:235-8. [PubMed 10877374]

13. Lewis PR, Phillips TG, Sassani JW. Topical therapies for glaucoma: what family physicians need to know. Am Fam Physician. 1999; 59:1871-9. [PubMed 10208706]

14. Derick RJ, Robin AL, Walters TR et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology. 1997; 104:131-6. [IDIS 381529] [PubMed 9022117]

15. Food and Drug Administration summary basis of approval on brimonidine tartrate 0.15% ophthalmic solution. NDA No. 21-262. Rockville, MD: undated. From the FDA website. Accessed March 25, 2002.

16. Katz LJ. Twelve-month evaluation of brimonidine-Purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002; 11:119-26. [PubMed 11912359]

17. Allergan, Inc, Irvine, CA; Personal communication.

18. Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma. 2000; 9:235-8. [PubMed 10877374]

19. Bausch & Lomb Pharmaceuticals, Inc. Brimonidine tartrate ophthalmic solution 0.2% prescribing information. Tampa, FL; 2003 May.

More Brimonidine Tartrate resources

• Brimonidine Tartrate Side Effects (in more detail)
• Brimonidine Tartrate Dosage
• Brimonidine Tartrate Use in Pregnancy & Breastfeeding
• Brimonidine Tartrate Drug Interactions
• Brimonidine Tartrate Support Group
• 3 Reviews for Brimonidine Tartrate - Add your own review/rating

• Alphagan Consumer Overview


• Alphagan P Prescribing Information (FDA)


• Alphagan P MedFacts Consumer Leaflet (Wolters Kluwer)


• Alphagan P Advanced Consumer (Micromedex) - Includes Dosage Information

Compare Brimonidine Tartrate with other medications

• Glaucoma, Open Angle
• Intraocular Hypertension

Flagyl Oral

Flagyl Oral may be available in the countries listed below.

Ingredient matches for Flagyl Oral

Metronidazole

Metronidazole benzoate (a derivative of Metronidazole) is reported as an ingredient of Flagyl Oral in the following countries:

• Spain

International Drug Name Search

Sertralina Bexal

Sertralina Bexal may be available in the countries listed below.

Ingredient matches for Sertralina Bexal

Sertraline

Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Sertralina Bexal in the following countries:

• Spain

International Drug Name Search

N-Mycin

N-Mycin may be available in the countries listed below.

Ingredient matches for N-Mycin

Natamycin

Natamycin is reported as an ingredient of N-Mycin in the following countries:

• Bangladesh

International Drug Name Search

Benazeplus AL

Benazeplus AL may be available in the countries listed below.

Ingredient matches for Benazeplus AL

Benazepril

Benazepril hydrochloride (a derivative of Benazepril) is reported as an ingredient of Benazeplus AL in the following countries:

• Germany

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Benazeplus AL in the following countries:

• Germany

International Drug Name Search

Cipro-Q

Cipro-Q may be available in the countries listed below.

Ingredient matches for Cipro-Q

Ciprofloxacin

Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Cipro-Q in the following countries:

• Germany

International Drug Name Search

Conclyte-PK

Conclyte-PK may be available in the countries listed below.

Ingredient matches for Conclyte-PK

Potassium Phosphate

Potassium Phosphate, Dibasic is reported as an ingredient of Conclyte-PK in the following countries:

• Japan

International Drug Name Search

Rokilide

Rokilide may be available in the countries listed below.

Ingredient matches for Rokilide

Roxithromycin

Roxithromycin is reported as an ingredient of Rokilide in the following countries:

• Japan

International Drug Name Search

Fevadol

Fevadol may be available in the countries listed below.

Ingredient matches for Fevadol

Paracetamol

Paracetamol is reported as an ingredient of Fevadol in the following countries:

• Bahrain


• Oman

International Drug Name Search

Bendex-400

Bendex-400 may be available in the countries listed below.

Ingredient matches for Bendex-400

Albendazole

Albendazole is reported as an ingredient of Bendex-400 in the following countries:

• South Africa

International Drug Name Search

Deca Duramin

Deca Duramin may be available in the countries listed below.

Ingredient matches for Deca Duramin

Nandrolone

Nandrolone 17ß-decanoate (a derivative of Nandrolone) is reported as an ingredient of Deca Duramin in the following countries:

• Japan

International Drug Name Search

Monocor

Monocor may be available in the countries listed below.

Ingredient matches for Monocor

Bisoprolol

Bisoprolol fumarate (a derivative of Bisoprolol) is reported as an ingredient of Monocor in the following countries:

• Canada

International Drug Name Search

Aciclovir-Genthon

Aciclovir-Genthon may be available in the countries listed below.

Ingredient matches for Aciclovir-Genthon

Acyclovir

Aciclovir is reported as an ingredient of Aciclovir-Genthon in the following countries:

• Luxembourg

International Drug Name Search

Prednisolone Atlantic

Prednisolone Atlantic may be available in the countries listed below.

Ingredient matches for Prednisolone Atlantic

Prednisolone

Prednisolone is reported as an ingredient of Prednisolone Atlantic in the following countries:

• Singapore

International Drug Name Search

doc Ibuprofen Schmerzgel

doc Ibuprofen Schmerzgel may be available in the countries listed below.

Ingredient matches for doc Ibuprofen Schmerzgel

Ibuprofen

Ibuprofen is reported as an ingredient of doc Ibuprofen Schmerzgel in the following countries:

• Germany

International Drug Name Search

Cyproplex

Cyproplex may be available in the countries listed below.

Ingredient matches for Cyproplex

Cyproterone

Cyproterone 17α-acetate (a derivative of Cyproterone) is reported as an ingredient of Cyproplex in the following countries:

• Belgium


• Czech Republic


• Latvia


• Lithuania


• Malaysia


• Peru


• Slovakia


• South Africa

International Drug Name Search

Miconazolnitraat Kring

Miconazolnitraat Kring may be available in the countries listed below.

Ingredient matches for Miconazolnitraat Kring

Miconazole

Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Miconazolnitraat Kring in the following countries:

• Netherlands

International Drug Name Search

Dermafast

Dermafast may be available in the countries listed below.

Ingredient matches for Dermafast

Miconazole

Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Dermafast in the following countries:

• Costa Rica


• Dominican Republic


• Guatemala


• Panama

International Drug Name Search

Ramipril Sandoz

Ramipril Sandoz may be available in the countries listed below.

Ingredient matches for Ramipril Sandoz

Ramipril

Ramipril is reported as an ingredient of Ramipril Sandoz in the following countries:

• Australia


• Austria


• Belgium


• Denmark


• Finland


• France


• Germany


• Netherlands


• Portugal


• Spain


• Sweden


• Switzerland

International Drug Name Search

Urolosin

Urolosin may be available in the countries listed below.

Ingredient matches for Urolosin

Tamsulosin

Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Urolosin in the following countries:

• Bangladesh


• Spain

International Drug Name Search

Aluminium Acetotartrate

ATC (Anatomical Therapeutic Chemical Classification)

S02AA04

Therapeutic Categories

Antiseptic

Antiinfective

Foreign Names

• Aluminii acetatis tartras (Latin)
• Aluminium acetat-tartrat (German)
• Acéto-tartrate d'aluminium (French)

Generic Names

• Aluminium aceticotartaricum (IS)
• Aluminium acetotartrat (IS)
• Aluminiumacetat-Tartrat-Lösung (PH: DAB 1999)
• Essig-weinsaure Tonerde (PH: Ph. Helv. 10)

Brand Names

• Alsol
  Athenstaedt, Germany; Egis, Hungary



• Altacet
  Lek, Poland



• Altix
  Herba Studio, Poland



• Aluminiumacetat-Tartrat-Lösung DAB
  Athenstaedt, Germany



• Cremor Aluminii Acetico-Tartarici
  Medicamenta, Czech Republic; Vulm, Slovakia



• Essigsaure Tonerde-Salbe
  Michallik, Germany



• Essitol
  Athenstaedt, Germany



• Euceta
  Novartis Consumer Health, Switzerland



• Fortacet
  Interdelta, Switzerland



• Instillatio Aluminii Acetico-tartarici
  Vulm, Slovakia



• Octanovy Krém
  Galvex, Slovakia



• Realderm Baby (Aluminium Acetotartrate and Zinc Oxide)
  Medical Concepts, Switzerland

International Drug Name Search

Glossary

IS	Inofficial Synonym
PH	Pharmacopoeia Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Italbenzol

Italbenzol may be available in the countries listed below.

Ingredient matches for Italbenzol

Albendazole

Albendazole is reported as an ingredient of Italbenzol in the following countries:

• Ecuador

International Drug Name Search

Laxans-ratiopharm

Laxans-ratiopharm may be available in the countries listed below.

Ingredient matches for Laxans-ratiopharm

Bisacodyl

Bisacodyl is reported as an ingredient of Laxans-ratiopharm in the following countries:

• Germany


• Luxembourg

International Drug Name Search

Desalfa

Desalfa may be available in the countries listed below.

Ingredient matches for Desalfa

Dexamethasone

Dexamethasone 21-isonicotinate (a derivative of Dexamethasone) is reported as an ingredient of Desalfa in the following countries:

• Italy

Lidocaine

Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Desalfa in the following countries:

• Italy

Neomycin

Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Desalfa in the following countries:

• Italy

International Drug Name Search

Oleandomicina

Oleandomicina may be available in the countries listed below.

Ingredient matches for Oleandomicina

Oleandomycin

Oleandomicina (DCIT) is also known as Oleandomycin (Rec.INN)

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Flossac

Flossac may be available in the countries listed below.

Ingredient matches for Flossac

Norfloxacin

Norfloxacin is reported as an ingredient of Flossac in the following countries:

• Italy

International Drug Name Search

Dermalife (Vitamin A)

Dermalife (Vitamin A) may be available in the countries listed below.

Ingredient matches for Dermalife (Vitamin A)

Retinol

Retinol palmitate (a derivative of Retinol) is reported as an ingredient of Dermalife (Vitamin A) in the following countries:

• New Zealand

International Drug Name Search

Fenotral

Fenotral may be available in the countries listed below.

Ingredient matches for Fenotral

Diphenhydramine

Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Fenotral in the following countries:

• Turkey

International Drug Name Search

Pacopan

Pacopan may be available in the countries listed below.

Ingredient matches for Pacopan

Paracetamol

Paracetamol is reported as an ingredient of Pacopan in the following countries:

• Thailand

Scopolamine

Scopolamine butylbromide (a derivative of Scopolamine) is reported as an ingredient of Pacopan in the following countries:

• Thailand

International Drug Name Search

Gentax

Gentax may be available in the countries listed below.

Ingredient matches for Gentax

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Gentax in the following countries:

• Austria


• Brazil


• Dominican Republic

International Drug Name Search

Doc Simvasta

Doc Simvasta may be available in the countries listed below.

Ingredient matches for Doc Simvasta

Simvastatin

Simvastatin is reported as an ingredient of Doc Simvasta in the following countries:

• Luxembourg

International Drug Name Search

Septix

Septix may be available in the countries listed below.

Ingredient matches for Septix

Erythromycin

Erythromycin is reported as an ingredient of Septix in the following countries:

• Germany

International Drug Name Search

Selpas

Selpas may be available in the countries listed below.

Ingredient matches for Selpas

Teprenone

Teprenone is reported as an ingredient of Selpas in the following countries:

• Japan

International Drug Name Search

Arcolan

Arcolan may be available in the countries listed below.

Ingredient matches for Arcolan

Ketoconazole

Ketoconazole is reported as an ingredient of Arcolan in the following countries:

• Brazil

International Drug Name Search

Calcidose

Calcidose may be available in the countries listed below.

Ingredient matches for Calcidose

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Calcidose in the following countries:

• France

International Drug Name Search

Claritromicina Labesfal

Claritromicina Labesfal may be available in the countries listed below.

Ingredient matches for Claritromicina Labesfal

Clarithromycin

Clarithromycin is reported as an ingredient of Claritromicina Labesfal in the following countries:

• Portugal

International Drug Name Search

Ofloxacina Poen

Ofloxacina Poen may be available in the countries listed below.

Ingredient matches for Ofloxacina Poen

Ofloxacin

Ofloxacin is reported as an ingredient of Ofloxacina Poen in the following countries:

• Argentina

International Drug Name Search

Calcitonina de Salmão Ostinate

Calcitonina de Salmão Ostinate may be available in the countries listed below.

Ingredient matches for Calcitonina de Salmão Ostinate

Calcitonin

Calcitonin is reported as an ingredient of Calcitonina de Salmão Ostinate in the following countries:

• Portugal

International Drug Name Search

Dirusid

Dirusid may be available in the countries listed below.

Ingredient matches for Dirusid

Furosemide

Furosemide is reported as an ingredient of Dirusid in the following countries:

• Bangladesh

International Drug Name Search

Quinapril Teva

Quinapril Teva may be available in the countries listed below.

Ingredient matches for Quinapril Teva

Quinapril

Quinapril is reported as an ingredient of Quinapril Teva in the following countries:

• Czech Republic


• Latvia


• Lithuania


• Poland


• Slovakia

Quinapril hydrochloride (a derivative of Quinapril) is reported as an ingredient of Quinapril Teva in the following countries:

• Belgium


• France


• Italy


• Slovakia


• Spain

International Drug Name Search

Chlorure de Calcium

Chlorure de Calcium may be available in the countries listed below.

Ingredient matches for Chlorure de Calcium

Calcium Chloride

Calcium Chloride is reported as an ingredient of Chlorure de Calcium in the following countries:

• Tunisia

International Drug Name Search

Renovia

Renovia may be available in the countries listed below.

Ingredient matches for Renovia

Lercanidipine

Lercanidipine hydrochloride (a derivative of Lercanidipine) is reported as an ingredient of Renovia in the following countries:

• Bulgaria

International Drug Name Search

Mucolin

Mucolin may be available in the countries listed below.

Ingredient matches for Mucolin

Ambroxol

Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Mucolin in the following countries:

• Brazil


• Greece

Carbocisteine

Carbocisteine is reported as an ingredient of Mucolin in the following countries:

• Mexico

International Drug Name Search